挪威103例基底细胞痣综合征患者的临床与遗传学发现
这项横断面研究在挪威全国范围内识别出109例基底细胞痣综合征(BCNS)患者,患病率至少为1.9/10万,其中103例纳入分析。研究确认了BCNS显著的表型变异,首次报告孤独症(4%)和癫痫(7%)的患病率,并发现PTCH1外显子1变异家系成员无BCC、牙源性角化囊肿或掌跖凹陷。
要点
- BCNS患者表型变异大,BCC中位48个,牙源性角化囊肿中位5个。
- 首次报告BCNS中孤独症患病率4%、癫痫7%,癫痫与颅内病灶相关。
- PTCH1外显子1变异家系成员未出现BCC、角化囊肿或掌跖凹陷。
核心结论
- 研究扩展了PTCH1致病性变异谱,揭示了新的基因型-表型关联,对BCNS管理和随访有启示。
研究设计与样本
- 横断面研究,通过奥斯陆大学医院皮肤科和两个国家级罕见病资源中心登记,并联系全国皮肤科、口腔科和遗传科医生识别患者。
- 共识别109例BCNS患者,其中103例同意纳入,收集结构化访谈、全身查体、电子病历、影像学和分子遗传分析数据。
主要发现
- 103例中61例有BCC(中位48个,范围1-1025),72例有牙源性角化囊肿(中位5个,范围1-30),43例有眼部异常,98例有骨骼异常。
- 孤独症患病率4%,癫痫患病率7%,并发现与癫痫相关的颅内病灶。
- PTCH1外显子1变异者(均属同一家系)均未出现BCC、牙源性角化囊肿或掌跖凹陷。
关键数值与推荐
- 挪威BCNS全国患病率至少为1.9/10万。
临床怎么用
- 对BCNS患者应进行多系统评估,包括皮肤、颌骨、眼部、骨骼及神经精神方面(癫痫、孤独症)。
- PTCH1外显子1变异者表型较轻,可能影响随访策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Basal cell naevus syndrome (BCNS) is a rare autosomal dominant condition characterized by early onset and multiple basal cell carcinomas (BCCs), skeletal and ocular abnormalities, and extracutaneous tumours and cysts. In most cases, BCNS is caused by a pathogenic variant in the tumour suppressor gene PTCH1. Pathogenic variants in SUFU account for a minority of cases. No clear genotype-phenotype associations between different PTCH1 variants have been established. OBJECTIVES: To identify all individuals with BCNS in Norway, characterize their clinical and genetic profiles, and investigate possible genotype-phenotype associations. METHODS: In this cross-sectional study, we approached all individuals with BCNS registered at the Department of Dermatology at Oslo University Hospital and two national resource centres for rare medical conditions. Dermatologists, dentists and geneticists across Norway were contacted in order to identify additional individuals with BCNS. Data were collected from structured interviews, whole-body physical examinations, electronic medical records, radiographic imaging and molecular genetic analyses. RESULTS: We identified 109 individuals with BCNS, indicating a national prevalence of BCNS of at least 1.9 per 100 000, of whom 103 agreed to be included. Clinical findings confirmed the considerable phenotypic variation in BCNS, including BCC in 61 individuals (median number of BCCs 48, range 1-1025), odontogenic keratocysts in 72 (median number of odontogenic keratocysts 5, range 1-30) and a wide spectrum of ocular and skeletal abnormalities in 43 and 98 individuals, respectively. This study is the first to report the prevalence estimates of autism (4%) and epilepsy (7%), as well as intracranial lesions associated with epilepsy, in BCNS. Genetic analyses identified a pathogenic or probable pathogenic PTCH1 variant in 93 individuals, while 5 individuals had variants of uncertain clinical significance. Twenty-one of the pathogenic PTCH1 variants were novel. None of the individuals with PTCH1 variants in exon 1, all belonging to the same family, exhibited BCCs, odontogenic keratocysts or palmoplantar pitting. CONCLUSIONS: This study expands the number of pathogenic PTCH1 variants, elucidates important clinical aspects in BCNS and reveals novel insight to genotype-phenotype associations, providing new implications for management and follow-up. Basal cell naevus syndrome, or ‘BCNS’ for short, is a rare genetic condition. It affects about 2 in every 100,000 individuals. It is also known as ‘Gorlin syndrome’. From a young age, individuals with the condition often develop a particular type of skin cancer called ‘BCC’. Many individuals with the condition can also experience jaw cysts and other health issues. Changes in a gene called ‘PTCH1’ cause most cases of the condition. But, how different genetic changes influence the health issues experienced by individuals with BCNS is not well understood. We aimed to find all individuals in Norway with the condition and describe their health and genetic backgrounds. To gather this information, we carried out interviews and physical examinations, and collected information from medical records, X-rays and genetic analyses. We identified 109 individuals with BCNS across Norway. Of these individuals, 103 agreed to take part in the study. Nearly all had a change in the PTCH1 gene. Twenty-one of the genetic changes had not been found before. Individuals with the condition experienced a variety of health issues. These included BCC, jaw cysts, eye problems and skeletal abnormalities. More individuals with the condition experienced epilepsy and autism than individuals in the general population of Norway. We also found a relationship between epilepsy and areas of abnormal brain tissue in individuals with the condition. Individuals with changes in a part of the PTCH1 gene called ‘exon 1’ had milder health issues than others. Our study provides new insights into the physical and genetic issues experienced in individuals with BCNS. Based on this, new ways to guide future care and monitoring are discussed.
引用
- Brandtzæg KH, von der Lippe C, Vestengen IK, et al. Clinical and genetic findings in 103 individuals in Norway with basal cell naevus syndrome. Br J Dermatol. 2026. PMID: 41129277. doi:10.1093/bjd/ljaf413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。